Increased susceptibility to systemic candidiasis in interleukin-6 deficient mice

Medical Mycology

Volumn 37, Issue 6, 1999, Pages 419-426

  Van Enckevort, F H J ^b   Netea, M G ^b   Hermus, A R M M ^b   Sweep, C G J ^b   Meis, J F G M ^b   Van Der Meer, J W M ^b   Kullberg, Bart Jan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; FEMALE; FUNGUS IMMUNITY; INFECTION SENSITIVITY; MALE; MOUSE; MOUSE MUTANT; NEUTROPENIA; NEUTROPHIL; NONHUMAN;

ANIMALS; CANDIDIASIS; DISEASE SUSCEPTIBILITY; FEMALE; INTERLEUKIN-1; INTERLEUKIN-6; MICE; NEUTROPHILS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; CANDIDA ALBICANS; FUNGI; NEGIBACTERIA; POSIBACTERIA;

EID: 0033405366     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-280X.1999.00247.x     Document Type: Article

References (39)

1. Rex JH, Bennett JE, Sugar AM. et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331: 1325-1330.
2. Tilg H, Dinarello CA, Mier JW. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators, Immunol Today 1997; 18: 428-432.
3. Hack CE, De Groot ER, Felt-Bersma RJ, et al. Increased plasma levels of interleukin-6 in sepsis. Blood 1989; 74: 1704-1710.
4. Suzuki Y, Yang Q, Conley FK, Abrams JS, Remington JS. Antibody against interleukin-6 reduces inflammation and numbers of cysts in brains of mice with toxoplasmic encephalitis. Infect Immun 1994; 62: 2773-2778.
5. Starnes HF Jr, Pearce MK, Tewari A, Yim JH, Zou JC, Abrams JS. Anti-1L-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-α challenge in mice. J Immunol 1990; 145: 4185-4191.
6. Liu Z, Simpson RJ, Cheers C. Role of IL-6 in activation of T cells for acquired cellular resistance to Listeria monocytogenes. J Immunol 1994; 152: 5375-5380.
7. Dalrymple SA, Lucian LA, Slattery R, et al. Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia. Infect Immun 1995; 63: 2262-2268.
8. Dalrymple SA, Slattery R, Aud DM, Krishna M, Lucian LA, Murray R. Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect Immun 1996; 64: 3231-3235.
9. van der Poll T, Keogh CV, Guirao X, Buurman WA, Kopf M, Lowry SF. Interleukin-6 gene-deficient mice show impaired defence against pneumococcal pneumonia. J Infect Dis 1997; 176: 439-444.
10. Ladel CH, Blum C, Dreher A, Reifenberg K, Kopf M, Kaufmann SH. Lethal tuberculosis in interleukin-6-dcficient mutant mice. Infect Immun 1997; 65: 4843-4849.
11. Suzuki Y, Rani S, Liesenfeld O, et al. Impaired resistance to the development of toxoplasmic encephalitis in interleukin-6-deficient mice. Infect Immun 1997; 65: 2339-2345.
12. Moskowitz NH, Brown DR, Reiner SL. Efficient immunity against Leishmania major in the absence of interleukin-6. Infect Immun 1997; 65: 2448-2450.
13. Perry LL, Feilzer K, Caldwell HD. Neither interleukin-6 nor inducible nitric oxide synthase is required for clearance of Chlamydia trachomatis from the murine genital tract epithelium. Infect Immun 1998; 66: 1265-1269.
14. Castro M, Bjoraker JA, Rohrbach MS, Limper AH. Candida albicans induces the release of inflammatory mediators from human peripheral blood monocytes. Inflammation 1996; 20: 107-122.
15. Yamamoto Y, Klein TW, Friedman H. Involvement of mannose receptor in cytokine interleukin-1beta (IL-1beta), IL-6, and granulocyte macrophage colony-stimulating factor responses, but not in chemokine macrophage inflammatory protein 1beta (MIP-1beta), MIP-2, and KC responses, caused by attachment of Candida albicans to macrophages. Infect Immun 1997; 65: 1077-1082.
16. Steinshamn S, Waage A. Tumor necrosis factor and interleukin-6 in Candida albicans infection in normal and granulocytopenic mice. Infect Immun 1992; 60: 4003-4008.
17. Romani L, Mencacci A, Cenci E, et al. Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J Exp Med 1996; 183: 1345-1355.
18. Kullberg BJ. Trends in immunotherapy of fungal infections. Eur J Clin Microbiol Infect Dis 1997; 16: 51-55.
19. Leijh PCJ, Van den Barselaar MT, Van Furth R. Kinetics of phagocytosis and intracellular killing of Candida albicans by human granulocytes and monocytes. Infect Immun 1977; 17: 313-318.
20. Van't Wout JW, Linde I, Leijh PCJ, Van Furth R. Contribution of granulocytes and monocytes to resistance against experimental disseminated Candida albicans infections. Eur J Clin Microbiol Infect Dis 1988; 7: 736-741.
21. Kullberg BJ, Netea MG, Curfs JHAJ, Keuter M, Meis JFGM, Van der Meer JWM. Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in non-neutropenic mice. J Infect Dis 1998; 177: 175-181.
22. Djeu JY, Blanchard DK, Halkias D, Friedman H. Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-γ and tumor necrosis factor. J Immunol 1986; 137: 2980-2984.
23. Kullberg BJ, Van't Wout JW, Hoogstraten C, Van Furth R. Recombinant interferon-γ enhances resistance to acute disseminated Candida albicans infection in mice. J Infect Dis 1993; 168: 436-443.
24. Kopf M, Baumann H, Freer G. et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994; 368: 339-342.
25. Lehrer RI, Cline MJ. Interactions of Candida albicans with human leukocytes and serum. J Bacteriol 1969; 98: 996-1004.
26. Kullberg BJ, Van't Wout JW, Van Furth R. Role of granulocytes in enhanced host resistance to Candida albicans induced by recombinant interleukin-1. Infect Immun 1990; 58: 3319-3324.
27. Kullberg BJ, Van't Wout JW, Van Furth R. No effect of recombinant human interleukin-1 on the numbers of peripheral blood and peritoneal leukocytes during an acute inflammation. Inflammation 1991; 15: 457-470.
28. Van't Wout JW, Linde I, Leijh PCJ, Van Furth R. Effect of irradiation, cyclophosphamide, and etoposide (VP-16) on number of peripheral blood and peritoneal leukocytes in mice under normal conditions and during acute inflammatory reaction. Inflammation 1989; 13: 1-14.
29. Lonnemann G, Endres S, Van der Meer JWM, Cannon JG, Koch KM, Dinarello CA. Differences in the synthesis and kinetics of release of interleukin-1α. interleukin-1β and tumor necrosis factor from human mononuclear cells. Eur J Immunol 1989; 19: 1531-1536.
30. Netea MG, Demacker PNM, Kullberg BJ. et al. Low-density-lipoprotein receptor deficient mice are protected against lethal endotoxinemia and severe Gram-negative infections. J Clin Invest 1996; 97: 1366-1372.
31. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-2147.
32. Romani L. The T cell response against fungal infections. Curr Opin Immunol 1997; 9: 484-490.
33. Puccetti P, Mencacci A, Cenci E, et al. Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J Infect Dis 1994; 169: 1325-1331.
34. Romani L, Puccetti P, Mencacci A. et al. Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. J Immunol 1994; 152: 3514-3521.
35. Cassone A, Palma C, Djeu JY, Aiuti F, Quinti I. Anticandidal activity and interleukin-1-beta and interleukin-6 production by polymorphonuclear leukocytes are preserved in subjects with AIDS. J Clin Microbiol 1993; 31: 1354-1357.
36. Ueta E, Umazume M, Yamamoto T, Osaki T. Enhancement of polymorphonuclear leukocyte (PMN) function by OK-432. Int J Immunopharmacol 1994; 16: 7-17.
37. Netea MG, Van Tits LHJ, Curfs JAHJ, et al. The increased susceptibility of TNFαLTα double knock-out mice to systemic candidiasis is due to defective recruitment and phagocytosis by neutrophils. In: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, 1998. Washington: Am Soc Microbiol, Abstract G44.
38. Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997; 94: 8093-8098.
39. Van der Meer JWM. Options for the treatment of serious infections with interleukin-1. Biotherapy 1989; 1: 313-317.